SLC5A2 and type 2 diabetes mellitus: In a very recent announcement, dapaglifloxin (Forxiga), the first of a class of inhibitors of the SGLT2 (SLC5A2) sugar transporters, has been approved in Europe for treatment of Type 2 diabetes.